New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
09:03 EDTMNKMallinckrodt to present new data for Xartemis XR, Pennsaid 2%
Mallinckrodt will present new data for two of its recently approved pain medications XARTEMIS XR Extended-Release Tablets and PENNSAID 2% during the 33rd Annual Scientific Meeting of the American Pain Society to be held April 30 - May 3, 2014 in Tampa, Florida. XARTEMIS XR is an oral medication indicated for the management of acute pain severe enough to require opioid treatment in patients for whom alternative treatment options are ineffective, not tolerated or would otherwise be inadequate. It is the first and only oxycodone HCI/acetaminophen combination for acute pain with immediate- and extended-release analgesia, providing fast-acting and long-lasting pain relief with 12-hour dosing for patients. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for the treatment of the pain of osteoarthritis of the knee(s). The data to be presented on XARTEMIS XR evaluates pharmacokinetics in different populations, as well as pooled safety data from Phase III trials. The first presentation of pivotal efficacy and safety results for PENNSAID 2% in the treatment of pain for osteoarthritis of the knee will also be presented, as well as an assessment of pharmacokinetics and tolerability compared with the 1.5% PENNSAID formulation.
News For MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:12 EDTMNKCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
October 15, 2014
06:42 EDTMNKMallinckrodt valuation remains compelling, says Piper Jaffray
Piper Jaffray believes Mallinckrodt's outlook for FY15 is conservative and that the risk/reward on shares is compelling. The firm raised its price target for the stock to $109 from $105 following the company's investor day and reiterates an Overweight rating on the name.
October 14, 2014
11:13 EDTMNKMallinckrodt management to meet with UBS
Subscribe for More Information
09:40 EDTMNKMallinckrodt aims to drive 'modest' growth in specialty controlled generics
Says aiming for profitability and revenue growth. Will continue to expand its pain management business. Looking to increase shareholder value, patient solutions and to drive top-line growth. Says aims to develop and acquire "durable, late stage complex products." Looking to invest in pipeline extensions of key portfolio assets. Aims to divest lower margin, slower growing business. Says sees future expansion in ophthalmology and dermatology. Looks to actively divest lower-growth businesses. Says durable assets, platforms positioned for sustained Specialty Pharmaceuticals growth. Says OFIRMEV is well positioned for growth in FY15 and beyond. Aims to up Acthar growth and initiate commercial efforts. Plans to enhance its science and technology investment. Comments made during the company's investor briefing.
07:34 EDTMNKMallinckrodt to host conference call
Subscribe for More Information
07:02 EDTMNKMallinckrodt sees FY15 adjusted EPS $6.70-$7.20, consensus $6.80
Subscribe for More Information
06:03 EDTMNKMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 10, 2014
07:16 EDTMNKAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
October 9, 2014
06:39 EDTMNKMallinckrodt price target raised to $110 from $95 at Jefferies
Jefferies raised its price target for Mallinckrodt shares to $110 ahead of the company's October 14 analyst day and keeps a Buy rating on the name. The firm says recent trends show continued strength for Ofirmev.
October 8, 2014
07:19 EDTMNKCBI to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use